Polycythemia Vera
What's New
Last Posted: Jan 16, 2024
- DNMT3A/TET2/ASXL1 mutations are an age-independent thrombotic risk factor in polycythemia vera patients: an observational study.
Adrián Segura-Díaz et al. Thromb Haemost 2024 - Mutational Landscape of Patients Referred for Elevated Hemoglobin Level.
Bhai Pratibha et al. Current oncology (Toronto, Ont.) 2022 29(10) 7209-7217 - [Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm].
Tan Y X et al. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2020 Jul 41(7) 576-582 - Mutational profiling in myelofibrosis: implications for management.
Bose Prithviraj et al. International journal of hematology 2019 Oct - Family Members at Higher Risk for Blood Cancers
P Harrison, Medscape, September 9, 2019 - Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Barbui Tiziano et al. Leukemia 2018 32(5) 1057-1069 - Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients?
Mina Alain Antoine et al. Current hematologic malignancy reports 2019 Apr - Classification and Personalized Prognosis in Myeloproliferative Neoplasms.
Grinfeld Jacob et al. The New England journal of medicine 2018 379(15) 1416-1430 - Local Coverage Determination (LCD): Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases (L37606)
The U.S. Centers for Medicare & Medicaid Services - Local Coverage Determination (LCD): Flow Cytometry (L33661)
The U.S. Centers for Medicare & Medicaid Services - Polycythemia Vera
From NHLBI health topic site
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Content Summary
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Content source: